In the future, multifactorial therapy in patients with T2D will likely consider SGLT2 inhibition as an equal or more important part of preventing complications in diabetes, thereby reducing the progression of cardiorenal disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.